TLR2 and inflammatory bowel disease: Finally, a Spanish research group found a significant association between five polymorphisms in TNFα or NFκB pathways and plasma concentrations of both infliximab (rs5030728 in TLR4 and rs11465996 in LY96) and adalimumab (rs1816702 in TLR2, rs2569190 in CD14, and rs3397 in TNFRS1B) in 154 children affected by IBD (Salvador-Martín et al., 2020) although different regimens and the number of patients in subgroups partly weakened those associations.